# Taurine Blood Pressure Randomized Trial: What the Evidence Says
Canonical: https://www.migaku.app/guides/taurine-blood-pressure-randomized-trial-evidence-review
Category: evidence-review
Summary: Taurine Blood Pressure Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are
Last reviewed: 2026-05-20
Reviewed by: Migaku Evidence Review
# Taurine Blood Pressure Randomized Trial: What the Evidence Says

## Quick Answer

Taurine Blood Pressure Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 systematic review, 1 narrative review.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| Taurine supplementation as a therapeutic strategy for cellular senescence and chronic inflammation in long COVID: a systematic review and meta-analysis | systematic review | 1 | 2026-03-10 | 10.1186/s12879-026-13009-y |
| Vitamins and nutraceuticals in glaucoma research | narrative review | 3 | 2026-02-04 | 10.1177/11206721261419640 |

## What The Sources Report

- Higher risk is associated with female sex, advanced age, smoking, elevated body mass index, multimorbidity, and greater acute disease severity. [Wang Kaiming (2026); evidence level 1]
- Although the overall risk of PASC complications has declined over time, many individuals continue to grapple with persistent neurological, pulmonary, cardiovascular, metabolic, and gastrointestinal disorders years beyond their initial infection. [Wang Kaiming (2026); evidence level 1]
- Importantly, while elevated intraocular pressure (IOP) is a well-established risk factor and the only available treatment target, it is neither necessary nor sufficient for the development of glaucoma, as evidenced by the existence of normal-tension glaucoma and the observation that many patients continue to progress despite achieving target IOP levels. [Hui Flora (2026); evidence level 3]
- It is estimated that the number of individuals affected by glaucoma will continue to rise, with substantial socioeconomic impact due to vision loss and associated disability.Age is the most prominent risk factor, but genetic predisposition, vascular dysregulation, and systemic metabolic dysfunction have also been implicated in disease susceptibility and progression. [Hui Flora (2026); evidence level 3]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For taurine blood pressure randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Wang Kaiming (2026). Taurine supplementation as a therapeutic strategy for cellular senescence and chronic inflammation in long COVID: a systematic review and meta-analysis. DOI: 10.1186/s12879-026-13009-y. PMCID: PMC13085605. PMID: 41803812. License: https://creativecommons.org/licenses/by-nc-nd/4.0/ http://creativecommons.org/licenses/by-nc-nd/4.0/ This article is .... https://pmc.ncbi.nlm.nih.gov/articles/PMC13085605/
- Hui Flora (2026). Vitamins and nutraceuticals in glaucoma research. DOI: 10.1177/11206721261419640. PMCID: PMC13091925. PMID: 41637226. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13091925/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.